Oct 12, 2022 8:05am EDT Ensysce Biosciences, Inc. Announces Participation in LD Micro Main Event XV Conference
Sep 22, 2022 8:05am EDT Ensysce Biosciences Announces Initiation of Second Human Abuse Potential Study, Being Conducted by DVCR
Sep 21, 2022 8:05am EDT Ensysce Biosciences to Present at Benzinga All Access Event on Friday, September 23, 2022
Aug 31, 2022 11:55am EDT Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce’s PF614-MPAR, a Novel Opioid Designed to Prevent Abuse and Overdose
Aug 31, 2022 8:05am EDT Ensysce Biosciences Debuts Redesigned Company Website to Highlight its TAAP(TM) and MPAR(TM) Technologies and Growing Product Pipeline
Aug 23, 2022 8:05am EDT Ensysce Biosciences Announces Completion of Clinical Portion of Human Abuse Potential Trial PF614-103
Aug 17, 2022 8:01am EDT Ensysce Biosciences Releases Updated Investor Presentation Ahead of Corporate Update Call